Lunaphore appoints Alice Feng as Chief Financial Officer
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced that Alice T. Feng will join the Lunaphore leadership team as Chief Financial Officer, effective January 31, 2022. Ms. Feng brings over two decades of finance and corporate development leadership experience as well as investment banking expertise, participating in over 30 merger and acquisition and financing transactions with aggregate transaction value of $45 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005433/en/
Alice Feng (Photo: Lunaphore)
“Alice brings deep expertise in corporate development and the capital markets and will play an instrumental role in our fundraising activities and leading the development of new partnerships as the company continues to expand globally,” said Ata Tuna Ciftlik, Ph.D., Chief Executive Officer of Lunaphore. “We are excited to work with Alice to achieve Lunaphore’s ambitious goals as we bring spatial biology into the mainstream.”
Ms. Feng most recently served as Chief Financial Officer of Scripps Research, a world-renowned biomedical research institution in San Diego, California. In this role, Ms. Feng was an instrumental member of the executive team that supported all of Scripps’ financial strategy and operations. She joined as Senior Director of Corporate Development and Finance in 2017.
Prior to joining Scripps Research, Ms. Feng worked with Scripps Health and Aetna, as the Senior Director of Corporate Development, where she led all aspects of M&A including due diligence, deal structure, valuation and negotiation. Prior to that, she spent over 11 years in investment banking, initially with a bulge-bracket firm, Merrill Lynch, and later with a boutique investment bank, Morgan Joseph.
Ms. Feng has long been passionate about healthcare. She received a B.S. in Business Economics and Microbiology and Molecular Genetics from the University of California, Los Angeles, and worked in academic research laboratories studying genetics as well as volunteering in local hospitals.
“I am particularly excited to join the Lunaphore team and help lead the company during this important stage of growth,” said Ms. Feng. “I look forward to raising Lunaphore’s financial profile as it executes on its vision of making spatial biology methods accessible to researchers around the world.”
To learn more about Lunaphore, please visit: https://lunaphore.com/
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Lunaphore Corporate Communications
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed
European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialise cilta-cel.2 “Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival. Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in Haematology,
SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 06:30:00 CEST | Press release
SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac
Lenovo Group: Full Year Financial Results 2021/2226.5.2022 06:19:00 CEST | Press release
Lenovo Group (HKSE: 992) (ADR: LNVGY) today announced record fiscal year results for the Group, with historic highs for both profit and revenue. Annual net income reached the US$2 billion mark, up 72% year on year, with revenue growing by US$10 billion for the second year running to over US$71 billion. All main business groups were profitable for the full fiscal year - with strong growth momentum in mobile, infrastructure, and solutions and services businesses. Lenovo successfully overcame macro-environmental challenges and demonstrated both agility and resilience as it navigated industry-wide supply shortages, pandemic disruption, geopolitical uncertainties, and higher inflation to deliver a record year. The digital and intelligent transformation trend continues to accelerate, presenting the Group with strong growth opportunities. More than 50% of companies now have digitalization as part of their corporate strategy, up from just over one third two years ago. The hybrid work model is
Exscientia Business Update for First Quarter 202225.5.2022 22:01:00 CEST | Press release
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-designed medicines utilising the breadth of our end-to-end platform of AI-driven capabilities from target prioritisation, to drug engineering and patient selection. At this year's American Association of Cancer Research (AACR) Annual Meeting, we highlighted our advancements in this area, including how AI-enabled drug design can help create drug candidates for challenging targets in oncology. In addition, we sho
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom